Semester
Spring
Date of Graduation
2014
Document Type
Dissertation
Degree Type
PhD
College
School of Pharmacy
Department
Pharmaceutical Sciences
Committee Chair
Rae R. Matsumoto
Committee Co-Chair
Andrew Coop
Committee Member
Stephen G. Graber
Committee Member
Jason D. Huber
Committee Member
Charles D. Ponte
Abstract
The three opioid receptor subtypes, mu (mu), delta (delta) and kappa (kappa) have long been associated with analgesia. Traditional opioid analgesics exert their effects through mu receptors located in the CNS. Recent studies suggest that the development of opioid analgesics displaying dual properties of mu agonism and delta antagonism could be of benefit by retaining potent analgesic properties while reducing the development of tolerance with chronic administration. UMB 425 displays high affinity at the mu receptor (K i = 3.2 +/- 0.14 nM), moderate affinity at the delta and kappa receptor. In vitro [35S]GTPgammaS functional assay results indicate that UMB 425 acts as partial agonist at the mu receptor, whilst having competitive antagonistic properties at the delta receptor. UMB 425 displays potent acute analgesic activity in vivo for both the hot plate and tail-flick assays, comparable to morphine itself. Naloxone, a non-selective opioid antagonist, and nor-BNI, a selective kappa-antagonist, pretreatment studies were performed to ensure proper opioid-induced analgesic mechanisms. Naloxone attenuates the analgesic effects induced by an acute ED90 of UMB 425, while nor-BNI shows no significant reduction. A chronic dosing paradigm was designed to determine UMB 425 induced analgesic tolerance. UMB 425 maintains significantly higher levels of analgesia compared to morphine on the fifth day of this chronic dosing paradigm. A dose-response challenge performed on the sixth day of this paradigm indicates a smaller shift in respective ED50 values for UMB 425 as compared to morphine for both the tail-flick (1.3-/6.4-fold) and hot plate (3.0-/7.8-fold) assays, effectively demonstrating reduced analgesic tolerance liabilities for UMB 425.
Recommended Citation
Healy, Jason Randall, "Pharmacological Characterization of Novel Opioid Receptor Ligands Aimed at Reducing the Development of Tolerance" (2014). Graduate Theses, Dissertations, and Problem Reports. 616.
https://researchrepository.wvu.edu/etd/616